Technology | Image Guided Radiation Therapy (IGRT) | June 30, 2016

Accuray Receives FDA Clearance for Radixact Image-Guided Radiation Therapy Platform

Next-generation "smart" system features more powerful linear accelerator, megavoltage CT imaging and helical treatment delivery for highly precise treatments

Accuray, Radixact Treatment Delivery Platform, image-guided radiation therapy, IGRT, FDA clearance

June 30, 2016 — Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform for radiation therapy. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

These next-generation hardware and software solutions, which together make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment.

The system features a more powerful linear accelerator, megavoltage computed tomography (MVCT) imaging and helical treatment delivery, so clinicians can apply highly conformal and homogenous dose distributions to any target volume while precisely sparing normal healthy tissue during each treatment fraction. The new Accuray Precision Treatment Planning System with smart, automated workflows and midcourse decision-making tools enables clinicians to adapt delivery to changes in tumor size, shape and location within the patient.

According to Jennifer Smilowitz, Ph.D., clinical associate professor University of Wisconsin School of Medicine and Public Health, who was involved in the development of the new radiation therapy technology, "The Radixact System builds upon the unique strengths of the TomoTherapy platform. Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT), an extremely accurate form of radiation therapy) to an expanded range of patients. New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department."

Accuray will initiate commercial release of the Radixact System late in the first quarter of fiscal year 2017 (July - September 2016).

For more information: www.accuray.com

Related Content

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...